Kura Oncology (KURA)

$KURA AtomicAlerts Scalp Alert Direction: SHORT Entry: $11.98 TP1: $11.28 | TP2: $10.58 | TP3: $9.88 Stop Loss: $12.58 👉 https://atomicalerts.com

1ightning® Premium Options Alert (Actionable) Ticker: $KURA Contract: Dec 19 $13C Entry: 0.60 Exit: 0.89 Return: +48.37% ROI Unlock VIP Access → https://1ightning.com

1ightning® Premium Options Alert (Actionable) Ticker: $KURA Contract: Dec 19 $13C Entry: 0.60 Exit: 0.89 Return: +48.37% ROI Unlock VIP Access → https://1ightning.com

Enter: $KURA Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.23 - $1.40 Sell Price: $2.80 Profit : +128% (Turn every $1 into $2.28) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

$KURA this has big mountain of resistance above 12$. Patience is key

$KURA I still can’t believe this hasn’t broken out to $20+. FDA approved drug that is literally best in class, best safety profile and combinability with other drugs. Ultra impressive pipeline including frontline multi billion dollar TAM. Nearly 200 million in milestone payments in the last couple of months with a lot more to come With so much of the float locked up by Tutes, i can only think we just need more eyes on Kura. The ASH conference this week does just that. It should heat up. MM can’t keep this down forever, they will try.

$KURA breaking 52 week high today? 😉

$KURA Breaking 12 today ?

Hedge Alert Live - Protect Your Portfolio Contract: $KURA $11.00 Put · DEC 19, 2025 Exp Entry Price: $0.59 - $0.60 Exit Price Target: $1.34 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

1ightning® Premium Options Alert (Actionable) Ticker: $KURA Contract: Dec 19 $12C Entry: 1.05 Exit: 1.59 Return: +51.25% ROI Unlock VIP Access → https://1ightning.com

$KURA Data incoming Followed by investors call Frontline triple threat Ven + Aza + ZIFTO = Bullish AF

$KURA Back in the 12’s. Incredibly undervalued. Should be at $20. Super

$KURA still very undervalued to me. pro forma cash = $740 million + $180 million remaining in near-term milestones on its way. only $1 billion market cap. market is not currently ascribing any value to a best in class menin inhibitor w/ multibillion $ potential in first line. and... i'm even more intrigued by their pipeline early clinical farnesyl transferase inhibitor (darlifarnib) that wall street doesn't even talk about. the market potential is 10x+ that of aml menin inhibitor class.

$KURA Good summary…thanks for sharing, now let’s get going!💥🚀💰

$KURA — Investor Announcement Preview (Next Monday) Direct Follow-Up to Monday’s ASH Combination Data Presentation Overall Takeaway: KURA’s investor announcement next Monday is positioned to be extremely bullish, serving as an immediate follow-up to their ASH presentation occurring earlier the same day. The company is expected to expand on the combination-therapy results for their lead approved asset, particularly in earlier-line and potential frontline settings, reflecting very high internal confidence in the upcoming ASH data. ⸻ 1. Monday’s Investor Update Will Expand on the ASH Combination Results KURA has intentionally scheduled the investor call just hours after their ASH presentation, a strong signal that the company believes the data will be meaningful and positively received. The Monday update will provide: • Deep interpretation of the ASH combination dataset • Context for efficacy, durability, and clinical benefit • Insights into potential treatment-effect signals • Discussion of synergy in earlier-line and frontline settings • Commercial implications and how the data expand the asset’s strategic positioning • A forward development strategy based on Monday’s results Companies rarely schedule immediate post-data communication unless they expect market-moving results. ⸻ 2. Earlier-Line & Frontline Opportunity Could Expand TAM by 5×+ If the combination data show favorable signals in: • Efficacy • Durability • Treatment effect • Progression prevention then KURA’s lead asset could meaningfully expand into earlier-line or even frontline therapy. Such a shift would: • Expand total addressable market (TAM) by 5× or more • Greatly increase eligible patient volume • Lengthen treatment duration • Strengthen combination adoption dynamics • Position KURA for multi-billion–dollar commercial upside This represents one of the largest expansion opportunities in the company’s history. ⸻ Bottom Line KURA enters Monday with one of the most bullish setups in the space: • ASH combination data released Monday morning • Investor announcement immediately afterward • Potential 5×+ TAM expansion if early-line/frontline signals hold • Strong internal confidence implied by communication timing • A realistic pathway toward establishing the lead asset as a frontline combination standard If the ASH combination results align with expectations, KURA could experience a significant value re-rating beginning next week.

$KURA again. No one cares about a random failed P1

$KURA Competitior's drug failed. A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies. https://www.targetedonc.com/view/menin-inhibitor-ds-1594b-lacks-efficacy-in-r-r-aml-and-all

Enter: $KURA Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.25 - $1.31 Sell Price: $2.11 Profit : +69% (Turn every $1 into $1.69) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

$KURA Good thing I bought that 1k right at market open in $11.30s. Back to $12 we go!!

$KURA Share Price: $11.15 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $3.97 – $4.90 Target Zone: $7.11 – $8.69 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

$KURA ASH